Lombard Medical Technologies PLC Notice of AGM and Annual Report and Accounts (8719D)

TIDMLMT

RNS Number : 8719D

Lombard Medical Technologies PLC

02 May 2013

Lombard Medical Technologies PLC

("Lombard Medical" or "the Company")

Notice of AGM and Annual Report and Accounts

London, UK, 2 May 2013 - Lombard Medical Technologies PLC (AIM:LMT), the specialist medical technology company focussed on innovative vascular products, announces that the Annual General Meeting of the Company will be held at the offices of Berwin Leighton Paisner LLP, Adelaide House, London Bridge, London EC4R 9HA at 11.00 p.m. on 23 May 2013.

The Notice of Annual General Meeting and the annual report and accounts for the year ended 31 December 2012 have been posted to shareholders. Electronic copies of these documents are available on the Company's website at www.lombardmedical.com.

-Ends-

 
 Lombard Medical Technologies PLC           Tel: 01235 750 800 
 Simon Hubbert, Chief Executive Officer 
  Ian Ardill, Chief Financial Officer 
 Canaccord Genuity Limited                  Tel: 020 7523 8000 
  Lucy Tilley / Henry Fitzgerald O'Connor 
  / Dr. Julian Feneley 
 FTI Consulting                             Tel: 020 7831 3113 
  Simon Conway / Susan Stuart / Victoria 
  Foster Mitchell

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.2 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company's lead product, Aorfix(TM), is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix(TM) is currently being commercialised in the EU, and has been approved by the FDA in the U.S. It is the only stent graft approved for AAA neck angulations of up to 90 degrees. Plans are currently underway to launch Aorfix(TM) in the US later this year through the group's own direct sales force, focusing on patients with tortuous aneurysm neck anatomy between 60 and 90 degrees in line with the products unique label. Aorfix(TM) is the first AAA stent graft not of U.S. origin to gain FDA approval.

The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.

Further background on the Company can be found at www.lombardmedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFVIETIFIIV

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Oct 2024 to Nov 2024